Pharmaco - Press Releases

Date	Title	Company
11-May-2022	Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission	Relief Therapeutics Holding SA
10-May-2022	ALTURiX Acquires UK and Ireland Rights to Metolazone	ALTURiX
10-May-2022	F-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update	F-star Therapeutics
10-May-2022	Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation	Evotec SE
10-May-2022	Evotec and Bristol Myers Squibb extend and expand strategic partnership	Evotec SE
10-May-2022	Introducing a new industry standard with new Crystal16	Technobis Crystallization Systems
10-May-2022	Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028	Roche
10-May-2022	Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics	Jazz Pharmaceuticals
10-May-2022	AlzeCure presents the science behind NeuroRestore and TrkA-NAM at drug development conference	AlzeCure
10-May-2022	Moberg Pharma´s Interim report January - March 2022	Moberg Pharma
10-May-2022	Moberg Pharma begins patient enrollment in North American phase 3 study	Moberg Pharma
10-May-2022	FORXIGA (DAPAGLIFLOZIN) ACCEPTED FOR USE IN SCOTLAND FOR THE TREATMENT OF ADULT PATIENTS WITH CHRONIC KIDNEY DISEASE	AstraZeneca
10-May-2022	BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights	BioXcel Therapeutics
10-May-2022	Achilles Therapeutics Doses First Patient with Higher-dose cNeT in Phase I/IIa CHIRON Trial in Advanced NSCLC and Initiates Enrollment in Cohort B of the THETIS Trial (cNeT + PD-1 checkpoint inhibitor) in Metastatic Malignant Melanoma	Achilles Therapeutics
10-May-2022	Almirall delivers good business performance in Q1 and reiterates full year 2022 guidance	Almirall
10-May-2022	SYNLAB AG: SYNLAB Medical Congress: making healthcare future-proof with advanced diagnostics	SYNLAB AG
10-May-2022	APONTIS PHARMA continues strong profitable growth in Q1 2022	APONTIS PHARMA AG
10-May-2022	Formycon AG and ATHOS KG announce closing of transaction to acquire biosimilar assets FYB201 and FYB202 as well as Bioeq GmbH	Formycon AG
09-May-2022	Disclosure on share buy-back according to Article 2 (1) of the Delegated Regulation (EU) No. 2016/1052 and Article 5 (1) Regulation (EU) No 2014/596 (Market Abuse Regulation)	SYNLAB AG
09-May-2022	Heidelberg Pharma AG and Partner Huadong Receive all Approvals for the Announced Transaction from the Authorities and Plan Capital Measure	Heidelberg Pharma AG